The Indian Journal of Pediatrics

, Volume 79, Issue 2, pp 229–237 | Cite as

Predicting Response to Growth Hormone Treatment

  • Leena Patel
  • Peter E. Clayton
Symposium on Growth Hormone


Despite extensive experience over the past 25 y in managing growth failure with growth hormone (rhGH), predicting treatment efficacy in individual children remains a challenge. In this paper, the authors present the methods that are currently available to clinicians for predicting the growth response, and other more sophisticated techniques which have the potential to pave the way for individualised therapy in the future.


Growth hormone Growth failure Growth prediction Growth hormone response Molecular biomarkers 


Conflict of Interest


Role of Funding Source



  1. 1.
    Richmond E, Rogol AD. Current indications for growth hormone therapy for children and adolescents. Endocr Dev. 2010;18:92–108.PubMedCrossRefGoogle Scholar
  2. 2.
    Takeda A, Cooper K, Bird A, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1–209.PubMedGoogle Scholar
  3. 3.
    Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ. 2011;342:c7157. doi: 10.1136/bmj.c7157.PubMedCrossRefGoogle Scholar
  4. 4.
    Cohen P, Rogol AD, Deal CL, et al. 2007 ISS Consensus Workshop participants: consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93:4210–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92:804–10.PubMedCrossRefGoogle Scholar
  6. 6.
    EU Summary of Product Characteristics (SPC) for GH therapy in SGA with lack of catch up (
  7. 7.
    Spagnoli A, Spadoni GL, Cianfarani S, Pasquino AM, Troiani S, Boscherini B. Prediction of the outcome of growth hormone therapy in children with idiopathic short stature. A multivariate discriminant analysis. J Pediatr. 1995;126:905–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Bakker B, Frane J, Anhalt H, Lippe B, Rosenfeld RG. Height velocity targets from the National Cooperative Growth Study for first-year growth hormone responses in short children. J Clin Endocrinol Metab. 2008;93:352–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Schonau E, Westermann F, Rauch F, et al. A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur J Endocrinol. 2001;144:13–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Ranke MB, Lindberg A, Chatelain P, et al. KIGS International Board. Kabi Pharmacia International Growth Study. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone in prepubertal children with idiopathic growth hormone deficiency. J Clin Endocrinol Metab. 1999;84:1174–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Blethen SL, Baptista J, Kuntze J, Foley T, LaFranchi S, Johanson A. Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. The Genentech Growth Study Group. J Clin Endocrinol Metab. 1997;82:418–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Van den Broeck J, Massa GG, Attanasio A, et al. Final height after long-term growth hormone treatment in Turner syndrome. European Study Group. J Pediatr. 1995;127:729–35.PubMedCrossRefGoogle Scholar
  13. 13.
    Haffner D, Wühl E, Schaefer F, Nissel R, Tönshoff B, Mehls O. Factors predictive of the short- and long-term efficacy of growth hormone treatment in prepubertal children with chronic renal failure. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Am Soc Nephrol. 1998;9:1899–907.PubMedGoogle Scholar
  14. 14.
    Bang P, Bjerknes R, Dahlgren J, et al. A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. Horm Res Paediatr. 2011 Jan 12. [Epub ahead of print] PubMed PMID: 21228552.Google Scholar
  15. 15.
    Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG. Effects of dose and gender on the growth and growth factor response to GH in GH deficient children: implications for efficacy and safety. J Clin Endocrinol Metab. 2002;87:90–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Rogol AD, Blethen SL, Sy JP, Veldhuis JD. Do growth hormone (GH) serial sampling, insulin-like growth factor-I (IGF-I) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy? Clin Endocrinol (Oxf). 2003;58:229–37.CrossRefGoogle Scholar
  17. 17.
    Rosenfeld RG. Editorial: the pharmacogenomics of human growth. J Clin Endocrinol Metab. 2006;91:795–6.PubMedCrossRefGoogle Scholar
  18. 18.
    de Zegher F, Hokken-Koelega A. Growth hormone therapy for children born small for gestational age: height gain is less dose dependent over the long term than over the short term. Pediatrics. 2005;115:e458–62.PubMedCrossRefGoogle Scholar
  19. 19.
    Rosenfeld RG, Buckway C, Selva K, Pratt KL, Guevara-Aguirre J. Insulin-like growth factor (IGF) parameters and tools for efficacy: the IGF-I generation test in children. Horm Res. 2004;62:37–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Thalange NK, Price DA, Gill MS, Whatmore AJ, Addison GM, Clayton PE. Insulin-like growth factor binding protein-3 generation: an index of growth hormone insensitivity. Pediatr Res. 1996;39:849–55.PubMedCrossRefGoogle Scholar
  21. 21.
    Ranke MB, Lindberg A. Predicting growth in response to growth hormone treatment. Growth Horm IGF Res. 2009;19:1–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Ranke MB, Lindberg A. KIGS International Board Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab. 2010;95:1229–37.PubMedCrossRefGoogle Scholar
  23. 23.
    Ranke MB, Lindberg A. Observed and predicted total pubertal growth during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency, turner syndrome, short stature, born small for gestational age and idiopathic short stature: KIGS Analysis and Review. Horm Res Paediatr. 2011; Feb 25. [Epub ahead of print] PubMed PMID: 21358173.Google Scholar
  24. 24.
    Ranke MB, Lindberg A, Cowell CT, et al. KIGS International Board Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab. 2003;88:125–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Jain KK. Role of pharmacoproteomics in the development of personalised medicine. Pharmanogenomics. 2004;5:331–6.CrossRefGoogle Scholar
  26. 26.
    Ding J, List EO, Okada S, Kopchick JJ. Perspective: proteomic approach to detect biomarkers of human growth hormone. Growth Horm IGF Res. 2009;19:399–407.PubMedCrossRefGoogle Scholar
  27. 27.
    Chung L, Clifford D, Buckley M, Baxter RC. Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. J Clin Endocrinol Metab. 2006;91:671–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Chung L, Nelson AE, Ho KK, Baxter RC. Proteomic profiling of growth hormone-responsive proteins in human peripheral blood leukocytes. J Clin Endocrinol Metab. 2009;94:3038–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Andersson B, Hellgren G, Nierop AF, Hochberg Z, Albertsson-Wikland K. Proteins related to lipoprotein profile were identified using a pharmaco-proteomic approach as markers for growth response to growth hormone (GH) treatment in short prepubertal children. Proteome Sci. 2009;7:40.PubMedCrossRefGoogle Scholar
  30. 30.
    Hellgren G, Andersson B, Nierop AF, Dahlgren J, Hochberg Z, Albertsson-Wikland K. A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short stature. Proteome Sci. 2008;6:35.PubMedCrossRefGoogle Scholar
  31. 31.
    Amit T, Youdim MB, Hochberg Z. Does serum growth hormone (GH) binding protein reflect human GH receptor function? J Clin Endocrinol Metab. 2000;85:927–32.PubMedCrossRefGoogle Scholar
  32. 32.
    Dattani M, Preece M. Growth hormone deficiency and related disorders: insights into causation, diagnosis, and treatment. Lancet. 2004;363:1977–87.PubMedCrossRefGoogle Scholar
  33. 33.
    de Graaff LC, Argente J, van Meurs JB, Uitterlinden AG, Hokken-Koelega AC. Genetic polymorphisms in the locus control region and promoter of GH1 are related to serum IGF-I levels and height in patients with isolated growth hormone deficiency and healthy controls. Horm Res Paediatr. 2010;73:25–34.PubMedCrossRefGoogle Scholar
  34. 34.
    Wassenaar MJ, Dekkers OM, Pereira AM, et al. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2009;94:3721–30.PubMedCrossRefGoogle Scholar
  35. 35.
    Wan L, Chen WC, Tsai Y, et al. Growth Hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in Patients with GH deficiency. Pediatr Res. 2007;62:735–40.PubMedCrossRefGoogle Scholar
  36. 36.
    Costalonga EF, Antonini SR, Guerra-Junior G, Mendonca BB, Arnhold IJ, Jorge AA. The −202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency. J Clin Endocrinol Metab. 2009;94:588–95.PubMedCrossRefGoogle Scholar
  37. 37.
    van der Kaay DC, Hendriks AE, Ester WA, et al. Genetic and epigenetic variability in the gene for IGFBP-3 (IGFBP3): correlation with serum IGFBP-3 levels and growth in short children born small for gestational age. Growth Horm IGF Res. 2009;19:198–205.PubMedCrossRefGoogle Scholar
  38. 38.
    Costalonga EF, Antonini SR, Guerra-Junior G, et al. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and −202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency. Pharmacogenomics J. 2011 Apr 5. [Epub ahead of print] PubMed PMID: 21468024.Google Scholar
  39. 39.
    Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet. 2004;36:720–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Binder G, Baur F, Schweizer R, Ranke MB. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endorcrinol Metab. 2006;91:659–64.CrossRefGoogle Scholar
  41. 41.
    Blum WF, Machinis K, Shavrikova EP, et al. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. Eur J Endocrinol Metab. 2006;91:4171–4.CrossRefGoogle Scholar
  42. 42.
    Jorge AL, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJP. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention of deletion on first-year growth response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab. 2006;91:1076–80.PubMedCrossRefGoogle Scholar
  43. 43.
    Binder G, Trebar B, Baur F, Schweizer R, Ranke MB. Homozygosity of the d3-growth hormone receptor polymorphims is associated with a high total effect of GH on growth and a low BMI in girls with Turner Syndrome. Clin Endocrinol. 2008;68:567–72.CrossRefGoogle Scholar
  44. 44.
    Carrascosa A, Esteban C, Espadero R, et al. The Spanish SGA Study Group. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 μg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational age children: results from a two-year controlled prospective study in 170 Spanish patients. J Clin Endocrinol Metab. 2006;91:3281–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Tauber M, Ester W, Aurio F, on behalf of the NESTEGG group, et al. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 polymorphism. Clin Endocrinol. 2007;67:457–61.CrossRefGoogle Scholar
  46. 46.
    Carrascosa A, Audi L, Fernandez-Cancio M, et al. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age. J Clin Endocrinol Metab. 2008;93:764–70.PubMedCrossRefGoogle Scholar
  47. 47.
    Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab. 2001;86:1274–80.PubMedCrossRefGoogle Scholar
  48. 48.
    Kristrom B, Jansson C, Rosberg S, Albertsson-Wikland K. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment. J Clin Endocrinol Metab. 1997;82:2889–98.PubMedCrossRefGoogle Scholar
  49. 49.
    de Ridder MA, Stijnen T, Hokken-Koelega AC. Prediction model for adult height of small for gestational age children at the start of growth hormone treatment. J Clin Endocrinol Metab. 2008;93:477–83.PubMedCrossRefGoogle Scholar
  50. 50.
    Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824–54.PubMedCrossRefGoogle Scholar
  51. 51.
    Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res. 2003;13:113–70.PubMedCrossRefGoogle Scholar
  52. 52.
    Rietveld I, Janssen JA, van Rossum EF, et al. A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. Clin Endocrinol (Oxf). 2004;61:195–203.CrossRefGoogle Scholar
  53. 53.
    Alatzoglou KS, Dattani MT. Genetic causes and treatment of isolated growth hormone deficiency-an update. Nat Rev Endocrinol. 2010;6:562–76.PubMedCrossRefGoogle Scholar
  54. 54.
    Riedl S, Frisch H. Effects of growth hormone (GH) and insulin-like growth factor-I therapy in patients with gene defects in the GH axis. J Pediatr Endocrinol Metab. 2006;19:229–36.PubMedCrossRefGoogle Scholar
  55. 55.
    Ahmad T, Geffner M, Parks J, Brown M, Fisher L, Costin G. Short stature and metabolic abnormalities in two sisters with a 7.6-kb GH1 gene deletion. Growth Horm IGF Res. 2011 Jan 11. [Epub ahead of print]Google Scholar
  56. 56.
    Hasegawa Y, Fujii K, Yamada M, et al. Identification of novel human GH-1 gene polymorphisms that are associated with growth hormone secretion and height. J Clin Endocrinol Metab. 2000;85:1290–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Whatmore AJ, Patel L, Clayton PE. A pilot study to evaluate gene expression profiles in peripheral blood mononuclear cells (PBMCs) from children with GH deficiency and Turner syndrome in response to GH treatment. Clin Endocrinol (Oxf). 2009;70:429–34.CrossRefGoogle Scholar
  58. 58.
    Fernández-Pérez L, Nóvoa J, Ståhlberg N, et al. The effect of in vivo growth hormone treatment on blood gene expression in adults with growth hormone deficiency reveals potential biomarkers to monitor growth hormone therapy. Clin Endocrinol (Oxf). 2010;72:800–6.CrossRefGoogle Scholar
  59. 59.
    Gelb BD, Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet. 2006;15:R220–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Limal JM, Parfait B, Cabrol S, et al. Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab. 2006;91:300–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Rosenthal S, Cohen P, Clayton P, et al. Part II: defining and managing growth hormone treatment failure. Pediatr Endocrinol Rev. 2007;4:257–68.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2011

Authors and Affiliations

  1. 1.Department of Pediatric EndocrinologyRoyal Manchester Children’s HospitalManchesterUK
  2. 2.Child Health & Pediatric Endocrinology, NIHR Greater Manchester, Lancashire & South Cumbria Medicines for Children Research NetworkUniversity of Manchester, Manchester Academic Health Sciences CentreManchesterUK

Personalised recommendations